ORIYA
DEAD

Serial Number

87648361

Owner

Teva Pharmaceuticals USA, Inc.

Filing Date

Oct 17, 2017

Add to watchlist:

No watchlists yet
View on USPTO

ORIYA Trademark

Serial Number: 87648361

ORIYA is a trademark filed by Teva Pharmaceuticals USA, Inc. on October 17, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Teva Pharmaceuticals USA, Inc. (587 trademarks)

650 Cathill Road
Sellersville, PA 18960

Entity Type: 03

Trademark Details

Filing Date

October 17, 2017

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Mar 18, 2019 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Mar 16, 2019 ABN2
UNDELIVERABLE MAIL - COURTESY COPY MAILED
Aug 22, 2018 UNDC
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 18, 2018 GNFN
FINAL REFUSAL E-MAILED
Aug 18, 2018 GNFR
FINAL REFUSAL WRITTEN
Aug 18, 2018 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 26, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 26, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 26, 2018 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 29, 2018 GNRN
NON-FINAL ACTION E-MAILED
Jan 29, 2018 GNRT
NON-FINAL ACTION WRITTEN
Jan 29, 2018 CNRT
ASSIGNED TO EXAMINER
Jan 22, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 26, 2017 NWOS
NEW APPLICATION ENTERED
Oct 20, 2017 NWAP